Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized StudyDavid E. Griffith, Kevin Winthrop, Michael R. Loebinger et al.|American Journal of Respiratory and Critical Care Medicine|2018Cited by 343
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung DiseaseDavid E. Griffith, Kevin Winthrop, Rachel Thomson et al.|CHEST Journal|2021Cited by 52
Airway Clearance Techniques in BronchiectasisAshwin Basavaraj, Kevin Winthrop, Radmila Choate et al.|CHEST Journal|2020Cited by 47
The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research RegistryEdward Eden, Kevin Winthrop, Radmila Choate et al.|Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation|2019Cited by 42
Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry PatientsTimothy R. Aksamit, Beth Shoshanna Zha, Nicholas Locantore et al.|American Journal of Respiratory and Critical Care Medicine|2024Cited by 36